Neuropsychiatric presentations of antiphospholipid antibodies

ABSTRACT Antiphospholipid syndrome (APS) is a systemic disease which can affect the central nervous system (CNS) through thrombotic mechanisms prone to induce vascular damage: stroke or transient ischemic attack (TIA) on the arterial side, cerebral venous thrombosis on the venous side. Beside these...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2015-02, Vol.135 (Suppl.1), p.S56-S59
Main Authors: Gris, Jean-Christophe, Nobile, Benédicte, Bouvier, Sylvie
Format: Article
Language:English
Subjects:
Animals
Antibodies, Antiphospholipid - immunology
Antiphospholipid antibodies
Antiphospholipid syndrome
Antiphospholipid Syndrome - diagnosis
Antiphospholipid Syndrome - immunology
Brain Diseases - diagnosis
Brain Diseases - immunology
Hematology
Hematology, Oncology and Palliative Medicine
Human health and pathology
Humans
Life Sciences
Mental Disorders - diagnosis
Mental Disorders - immunology
Neurology
Psychiatry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Antiphospholipid syndrome (APS) is a systemic disease which can affect the central nervous system (CNS) through thrombotic mechanisms prone to induce vascular damage: stroke or transient ischemic attack (TIA) on the arterial side, cerebral venous thrombosis on the venous side. Beside these academic syndromic manifestations, some nonvascular neurological manifestations of antiphospholipid antibodies (aPLAbs) are progressively emerging, being associated with a wide range of polymorphic neurological, psychological and psychiatric manifestations. Animal models and in vitro experimental data support an immune-mediated pathogenesis, with direct binding and effect of aPLAbs on neurons and glial cells which are thought to occur after a disruption or a permeability alteration of the blood-brain barrier (BBB). The magnitude of the association and cellular and molecular mechanisms involved need to be further elucidated. No standard treatment is available for nonvascular neuropsychiatric manifestations associated with positive aPLAbs and specific developments are warranted.
ISSN:0049-3848
1879-2472
DOI:10.1016/S0049-3848(15)50445-3